Joint Venture Between BioDuro and Cenra Set to Increase Commercial API Manufacturing Capacity
The companies will integrate their strengths from early-stage development and commercial-scale GMP API manufacturing to offer clients an end-to-end API solution.
Global contract research, development, and manufacturing organization (CRDMO), BioDuro, has announced the establishment of a joint venture with Taiwanese pharmaceutical chemical manufacturer, Cenra API Solutions — also known as Chunghwa Chemical Synthesis & Biotech Co. Ltd. — in a March 3, 2026 press release (1). Through this new venture, BioDuro will add significant commercial-scale API manufacturing capacity at Cenra’s campus in Taipei, Taiwan, to its global network.
Cenra’s Taipei campus includes 10 GMP API production lines, offering a total reactor volume of over 350,000 L, which can support annual API output of up to 200 metric tons. Additionally, the campus has already been successfully inspected by key global regulatory authorities, including the U.S. FDA, EMA, Japan’s PMDA, and Taiwan’s TFDA (1).
“By combining BioDuro’s integrated CMC expertise with Cenra’s nearly six decades of GMP manufacturing excellence and enviable international regulatory history, our joint venture strengthens both companies’ global supply chain resilience and minimizes the risks of technology-transfers,” said Armin Spura, Ph.D., CEO of BioDuro, in the company press release (1). “This collaboration allows us to provide customers with truly integrated services and a drug substance solution that spans discovery chemistry, process R&D, regulatory starting materials, advanced intermediates, and clinical- to commercial-scale API production, both inside and outside mainland China, accelerating the advance of innovative therapies to market, for patients worldwide.”
“BioDuro serves more than 1,500 global customers annually with industry-leading R&D and manufacturing capabilities,” added Wayne Hsiao, President of Cenra API Solutions, in the press release (1). “We are excited to join forces to deliver highly integrated solutions and greater value to customers around the world.”
According to market research, the global API market is anticipated to reach a value of USD 397.28 billion by 2035, growing at a compound annual rate of 5.64% between 2026 and 2035. The expansion of this market is being driven by a variety of factors, such as the increasing prevalence of chronic and infectious diseases, growing demand for generic drugs, expansion of biopharmaceuticals, and advancements in pharmaceutical R&D (2).
References
BioDuro. BioDuro and Cenra Launch Joint Venture to Expand Resilient Global API Manufacturing Capacity. Press Release, March 3, 2026.
Cervicorn Consulting. Active Pharmaceutical Ingredient (API) Market Size, Share, Forecast 2026 to 2035.Market Research Report, March 19, 2025.